Core Viewpoint - Zhaoke Ophthalmology is considered an undervalued innovative ophthalmic drug company, with significant potential for growth as it approaches a clinical drug harvest period and has seen a stock price increase of approximately 140% this year, despite a low price-to-book ratio of less than 1 [4][15]. Product Pipeline and Market Potential - Zhaoke Ophthalmology has a comprehensive pipeline focusing on three main products: NVK002 for myopia control, a modified cyclosporine A eye gel for moderate to severe dry eye syndrome, and TAB014 for wet age-related macular degeneration (wAMD) [5][10][11]. - The NVK002 product, a low-concentration atropine eye drop, has received significant regulatory attention, with a simplified new drug application accepted and a new drug listing application approved for the 0.02% concentration [5][7]. - The market for myopia treatment is substantial, with over 40 million children in China being potential users, indicating a large growth opportunity for NVK002 [7][9]. Competitive Landscape - The competition for NVK002 is intense, with other companies like Xingqi Eye Medicine already having launched similar products. Zhaoke aims to differentiate itself by enhancing patient compliance and addressing the stability issues of atropine [8][9]. - The modified cyclosporine A eye gel has shown promising clinical results, with a patient compliance rate of 98.94%, and is expected to receive faster approval due to proactive communication with regulatory authorities [10][11]. Future Outlook - Zhaoke Ophthalmology aims to have a total of 12 products on the market within the next 18 months, which would significantly enhance its influence in the ophthalmic field [14][15]. - The company has also received orphan drug designation from the FDA for a treatment for retinoblastoma, indicating its commitment to expanding its product offerings [12]. - The CEO expressed confidence in the company's future, emphasizing the importance of timely product approvals and the potential for market growth in various ophthalmic conditions [17].